Literature DB >> 15125797

Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib.

Satoshi Komatsubara1, Satoshi Mori, Tasuku Mashiba, Jilliang Li, Kiichi Nonaka, Yoshio Kaji, Tomoyuki Akiyama, Kensaku Miyamoto, Yongping Cao, Jun Kawanishi, Hiromichi Norimatsu.   

Abstract

UNLABELLED: Effects of long-term suppression of bone remodeling by bisphosphonate were investigated in cortical bone of dog rib. Although microdamage was accumulated, BMD was increased without increasing cortical bone area. Consequently, the intrinsic material properties were not reduced.
INTRODUCTION: Recently, we have reported that long-term suppression of bone remodeling increases microdamage accumulation but is not necessarily associated with vertebral fragility because of compensated increase of bone mass and improved microarchitecture. This study aimed to investigate the effect of long-term suppression of bone remodeling by bisphosphonate on the degree of mineralization, accumulation of microdamage, and mechanical properties of cortical bone in the same dogs.
MATERIALS AND METHODS: Twenty-nine 1-year-old beagles (15 males, 14 females) were divided into three groups and treated daily with vehicle (CNT) or with incadronate at a dose of 0.3 (LOW) or 0.6 mg/kg/day (HIGH) orally for 3 years. After death, pQCT, histomorphometry, microdamage measurements, and three-point bending mechanical test were performed using the ninth rib.
RESULTS: Cortical BMD was increased in the incadronate-treated groups. Cortical activation frequency was suppressed by 82% and 70% in HIGH and LOW, respectively, compared with CNT, without impairment of mineralization. Microdamage accumulation was increased in both incadronate-treated groups. Although there were no significant differences in total and cortical area among the three groups, structural mechanical properties were significantly increased after incadronate treatment while intrinsic material properties were not changed in the incadronate-treated groups.
CONCLUSION: This study suggests that long-term suppression of bone remodeling by bisphosphonate increases microdamage accumulation. However, this was not necessarily associated with a reduction of intrinsic material properties probably because of an increased degree of mineralization. Copyright 2004 American Society for Bone and Mineral Research

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15125797     DOI: 10.1359/JBMR.040126

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  34 in total

Review 1.  The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing.

Authors:  Matthew R Allen
Journal:  Odontology       Date:  2011-01-27       Impact factor: 2.634

2.  Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects.

Authors:  Crystal K Tjhia; Clarita V Odvina; D Sudhaker Rao; Susan M Stover; Xiang Wang; David P Fyhrie
Journal:  Bone       Date:  2011-09-18       Impact factor: 4.398

3.  Serum osteoprotegerin concentration with strontium ranelate treatment for postmenopausal osteoporosis: an open, prospective study.

Authors:  Melek Eda Ertorer; Okan Bakiner; Inan Anaforoglu; Nurzen Sezgin; Nilgun Guvener Demirag; Neslihan Bascil Tutuncu
Journal:  Curr Ther Res Clin Exp       Date:  2007-07

Review 4.  Mineral changes in osteoporosis: a review.

Authors:  Dan Faibish; Susan M Ott; Adele L Boskey
Journal:  Clin Orthop Relat Res       Date:  2006-02       Impact factor: 4.176

5.  Studying the role of microcracks in the pathophysiology of BRONJ.

Authors:  Matthew R Allen
Journal:  Clin Oral Investig       Date:  2009-08-18       Impact factor: 3.573

6.  Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment.

Authors:  Matthew R Allen; David B Burr
Journal:  J Oral Maxillofac Surg       Date:  2008-05       Impact factor: 1.895

7.  Images in medicine - bisphosphonate induced atypical fracture.

Authors:  Riddhi Das Gupta; Sahana Shetty; Hesargatta Shyamsunder Asha; Sandeep Albert; Thomas Vizhalil Paul
Journal:  J Clin Diagn Res       Date:  2014-01-12

8.  Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model.

Authors:  Diana Olvera; Rachel Stolzenfeld; Joan C Marini; Michelle S Caird; Kenneth M Kozloff
Journal:  J Bone Miner Res       Date:  2018-05-07       Impact factor: 6.741

9.  In vivo microdamage is an indicator of susceptibility to initiation and propagation of microdamage in human femoral trabecular bone.

Authors:  Ziheng Wu; Anthony J Laneve; Glen L Niebur
Journal:  Bone       Date:  2013-02-28       Impact factor: 4.398

10.  Theoretical analysis of alendronate and risedronate effects on canine vertebral remodeling and microdamage.

Authors:  Xiang Wang; Antonia M Erickson; Matthew R Allen; David B Burr; R Bruce Martin; Scott J Hazelwood
Journal:  J Biomech       Date:  2009-03-12       Impact factor: 2.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.